Zacks was right on with JAZZ, KERX and Biogen when all were trading at under 50 cents. Jazz is at $150, KERX is at $13 and Biogen is at $450+++. They know that AVEO is going up, up, up!!!!
It'll pop to $.70 according to the technicals. The MMs are working actively today therefore the see saw action. There will be a nice climb over the next few weeks settling into the mid $1 range.
Strong buying through the end of the trading day. It'll push to the $9.50 range and then propel up.
The low trading volume recently indicates that the market is waiting on the next couple of events. The floor is cemented in. Higher revenue and lowered costs with a solid near term strategy in the next report should get the price in the range that you have indicated. It'll go up from there.
You are not a Long so why are you offering your biased opinion to a question not addressed to you? Can you not read what the poster's topic line? Dodd was brought in to turnaround this company. My relative was brought in for the same reason, as a turnaround executive. He also faced the delisting issue and he used the two grace periods wisely. Stock went from $.30 to $4 within a year....not bad, huh. I'm sure it would've been worth a lot more but the big dog wanted the company badly and paid handsomely for it.
Probably a lot of speculation that $13 is the absolute floor if a BO happens this month. It's a 50% profit at the least and I suspect it to go up much higher should that exit strategy materialize. HB probably negotiated out his golden parachute to hedge against the near future.
That's very possible as Denner is probably chomping at the bit. The recent analysis has a strong buy so the general opinion is this stock is way undervalued. It should be trading much higher given the advancement of the pipeline.
A relative of mine did the same thing for an East coast software company. I bought at $.30 and woke up to a $4/share buyout one morning by a big dog. Not a bad multiple return. He has a tremendous track record. I'd not stick around this stock if the ex CEO was still in place. Dodd can (and is succeeding) in commercializing this company. As other posters have noted, some great test results and this company can be following the path of DYAX.,
This long standing company is in the midst of a turnaround event. It was a crisis for a long time hence the price was beaten to a pulp. The corner has been turned. The large volume of trading today indicates a good run up over the next several weeks (as do the technical charts). I'm also anticipating AVEO to double within a few weeks. And I am not even charging you for my advice, lol.
I think that just about everybody would win if a BO happens this 1st half except maybe those who bought (and held) at the price peak. A 3x would bring those folks back towards break even. The BBJ published a good article and analysis of potential suitors but I think the original deals on the table are low. I'd tend to look at a 4x to 8x. In 2016 with progress then the multiples will just go up.
They will be granted another extension so mid-December to gain compliance, then a hearing, etc, etc
It's basic MM action. Last month the stock was going up and trading 20 million shares a day. Now it's a trickle at 250k so far today. A few impatient investors are moving on. The future is set for a nice ride up....hang on.
Yes. It is high risk and reward. I liked the R&D move over to the University system with the focus on commercialization and profit. 108 is the golden grail. It's good that the FDA sees a vision for 130. Dodd seems to be executing the strategy so the cash versus options short term is not a big deal since he's lowered expenses tremendously.
The heavy share trading today shows a lot of positive momentum for this stock. It can move very quickly to over $1, even to $2. A couple of solid PRs would boost it up along with the Strong Buy ratings.
I joined you Gold. I bought in at the floor level. I buy low too. Just furnished the house with hand cut crystal for 8 cents on the dollar. I need a few new luxury cars hence the VVUS buy.
He's competing for the most long winded documentary to take over War and Peace listed in the Guinness Book of World Records. It's his only credit to fame that he'll ever achieve.
Good points Gary. When the last split occurred a few years ago the total outstanding shares was around 21-22 million. Now they are over 90 million shares so the ATM was really cooking. It seems like a potential repeat but I'd throw it as the last option if I were allowed to have BOD vote. The last time they split right after the approval and did not take the extra grace period or hearing as options.
According to the listing requirements, the company has another 180 days (2nd compliance term) after June 16th to get the share price up. If this doesn't happen then the company can request a hearing with a plan to gain compliance. Meanwhile, the share trading on the NSDQ would not be affected until the hearing is over. If a split is taken prior to this then the BOD and Mgmt options will be severely under water. A four for one or eight for one split should be the last resort since the company has enough operational cash through 2016 given the layoffs and other expense reductions. It's interesting to note that Dodd took more cash than options for last year's compensation. They need to churn out more news and get an approval. 130 approval would mitigate the current lawsuits which they are going down that path.
Nice analysis! I see a move up to $5.7 to $6 this month and go on from there. With the consolidation going on in the diabetes industry, I'm confident that BO deals are getting sweeter as the market gets educated to Afrezza. TS is the golden goose to the golden egg. Hang tight. Shorts will start dropping like flies.